Sign up to receive our personalized investment offer.

Global Equities

9.9% profit on Rio Tinto PLC in our downside wiew

Rio Tinto EXIT

Fertiliser developer Agrimin Ltd said on Friday its unit had signed a farm-in deal with Rio Tinto for sale of up to a 75% stake in five copper-gold licenses it holds in the West Arunta region of Western Australia.

Rio Tinto PLC 20210224 16.35

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Contact our advisors through website chat 24/7.

7.4% profit on EBAY in our downtrend view

eBay Inc All exit

Elliott Investment Management Dissolves Share Stake In Ebay - Sec Filing.

eBay Inc All Sessions 20210210 16.35

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Contact our advisors through website chat 24/7.

8.5% profit on Barclays PLC in our uptrend view

Barclays PLC EXITBarclays PLC 20201216 14.10

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Contact our advisors through website chat 24/7.

13.8% profit on Nikola Corporation in our downtrend view

Nikola CorporationEXIT

Nikola Corp on Tuesday disclosed details on its hydrogen fuel-cell-powered product lineup that will include vehicles with a driving range of up to 900 miles. 

Nikola Corporation 20210205 16.33

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Contact our advisors through website chat 24/7.

21% profit on Zoom Communications in our downside view

Zoom Video Communications Inc exit

Zoom Video Communications Inc's video-conferencing platform was down for more than a thousand users on Wednesday, according to outage tracking website Downtector.com. Downdetector showed there were nearly 2,000 incidents of people reporting issues with Zoom at its peak.

Zoom Video Communications Inc All Sessions 20210219 16.33

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Contact our advisors through website chat 24/7.

8.5% profit on Royal Dutch Shell in our upside view

Royal Dutch Shell PLC exit

Royal Dutch Shell is changing the senior leadership of its operations in Britain as part of a global overhaul to cut costs and shift away from oil and gas to renewables and power.

Royal Dutch Shell PLC B LSE 20210212 16.34

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Contact our advisors through website chat 24/7.

During Covid-19 Pandemic, Biotech IPOs Already Surpass Record

So far this year, U.S.-listed biotech companies have raised roughly $9.4 billion in initial public offerings, already beating the $6.5 billion raised in all of 2018, the biggest year on record, according to Dealogic data going back to 1995. This year’s biotech issues have jumped an average of 34% on their first day of trading, the biggest average first-day pop for the sector since the tech boom in 2000.

The recent surge in biotech stocks extends beyond IPOs, as investors chase companies working on potential vaccines to combat Covid-19. They also anticipate the industry may benefit from more investment by governments in drug discovery and development. Still, there are reasons to be skeptical. Biotech stocks in general can tend to be volatile, depending on the success or failure of companies’ key drugs. Some longtime biotech investors are wary of the run-up and warn there are risks to chasing companies at early stages of development.

The Nasdaq Biotechnology Index is up 13% so far this year, compared with the S&P 500’s 3.7% rise. In June, as the coronavirus pandemic swirled, the exchange-traded fund issuer ETFMG launched a product that focuses specifically on companies engaged in the testing and treatments of infectious diseases. The fund, the Treatments, Testing and Advancements ETF, trades under the ticker GERM. Public companies are already taking advantage of the flood of money into the biotech sector by issuing more stock at a record pace. So far this year, biotech companies have raised more than $32 billion in follow-on offerings, already the most ever in a year, according to Dealogic. 

Screenshot 6

Many investors who have spent years analyzing and buying shares of biotech companies say the market’s enthusiasm for health-care companies might be overdone, particularly for companies that appear to be rising on bets that testing for Covid-19 vaccines will be successful. One company touting a vaccine candidate is Moderna Inc., MRNA -2.96% which has seen its market valuation balloon to nearly $30 billion, up from roughly $7 billion at the start of the year. Moderna, which codesigned the vaccine candidate with the National Institute of Allergy and Infectious Diseases, is embarking on a Phase 3 trial. Investors will soon have another coronavirus-related stock to bet on. A German biotech company, CureVac BV, is expected to list shares on the Nasdaq Stock Market in an IPO later this month, according to people familiar with the matter. 

Screenshot 72

 

Payments

Social

download follow on googleplus twitter2

Sign up to receive a personalized investment offer.